The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

June 15, 2017 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a significant clinical void, according to the document published in Arthritis Care & Research, April 2017.

You Might Also Like
  • Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain
  • Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome
  • Impact of Fatigue on Inflammatory Arthritis Merits More Research
Explore This Issue
June 2017
Also By This Author
  • Smartphone Apps Make Virtual House Calls

The Sjögren’s Syndrome Foundation effort was led by CEO Steven Taylor and Vice President for Research Katherine Moreland Hammitt. The guidelines represent the first phase of treatment guidelines for Sjögren’s syndrome and address the use of biologic agents, management of fatigue and inflammatory musculoskeletal pain. The first phase was chaired by Fredrick B. Vivino, MD, at Penn Presbyterian Medical Center, University of Pennsylvania. The next set of guidelines, which will be developed over the next couple of years, will look at several more of the 10 issues considered most important by the guidelines committee.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lead author Steven E. Carsons, MD, at NYU Winthrop Hospital Campus and professor of medicine at Stony Brook University School of Medicine, says the clinical practice guidelines “will be extremely valuable for clinicians who treat Sjögren’s and for payers as a guide to appropriate management strategies. These are the first formally constructed guidelines for Sjögren’s syndrome intended for U.S. practitioners, … and they provide some clarity toward a preferred approach to the management of the manifestations of Sjögren’s.”

The Sjögren’s Syndrome Foundation, founded about 35 years ago, was the first organization to raise awareness about the disorder, Dr. Carsons says. “On the basis of [its] efforts and efforts by others in Europe and elsewhere, there is now an awareness of Sjögren’s among patients and physicians.” This awareness has fostered a marked increase in research. “The culmination of all this interest and the environment of advances in so many other fields in rheumatology led to questions about what we can do about Sjögren’s, an area where we have not had a lot of good therapies and direction.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In recent years, there has been a “fairly significant uptick in the number of agents being developed for Sjögren’s, and quite a few clinical trials in the U.S., Europe and other countries are now enrolling [patients]. That is in stark contrast to even five years ago,” Dr. Carsons says. Also, earlier this year, the ACR and EULAR released classification criteria for primary Sjögren’s syndrome, intended to improve the comparison of results across clinical studies and to aid in recruitment of patients for trials.2

Guidelines Development

The Clinical Practice Guidelines Committee employed a systematic review of the literature to inform a consensus expert panel (CEP), Dr. Carsons says. Recommendations were formulated by the experts according to the available literature and extrapolation from management of similar circumstances in other rheumatic diseases. The CEP, comprising rheumatologists, dentists, ophthalmologists, nurses, patients and allied health professionals, used Delphi methodology to achieve a 75% or greater consensus among the 30–40 participants for each of the recommendations.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: biologic, Clinical, drug therapy, fatigue, guideline, inflammatory musculoskeletal disease, Pain, patient care, recommendation, Rheumatic Disease, Sjögren's syndrome, Sjögren's Syndrome Foundation, TreatmentIssue: June 2017

You Might Also Like:
  • Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain
  • Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome
  • Impact of Fatigue on Inflammatory Arthritis Merits More Research
  • New Consensus Recommendations Guide Sjögren’s Syndrome Management

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)